FISH ROS1 6q22 Rearrangement Test: Advanced Cancer Genetic Analysis
Understanding the FISH ROS1 6q22 Rearrangement Test
The FISH ROS1 6q22 Rearrangement Test represents a cutting-edge molecular diagnostic approach that plays a crucial role in modern precision oncology. This specialized genetic analysis detects specific chromosomal rearrangements involving the ROS1 gene located at chromosome 6q22, providing essential information for targeted cancer therapy selection.
As cancer treatment evolves toward personalized medicine, identifying specific genetic alterations becomes increasingly important. The ROS1 gene rearrangement occurs when the ROS1 gene fuses with various partner genes, creating abnormal fusion proteins that drive cancer growth. Detecting these rearrangements enables oncologists to select targeted therapies specifically designed to inhibit these abnormal proteins.
What Does the Test Measure and Detect?
The FISH ROS1 6q22 Rearrangement Test specifically identifies:
- Chromosomal rearrangements involving the ROS1 gene at 6q22
- Gene fusions that create abnormal ROS1 fusion proteins
- Specific breakpoints in the ROS1 gene region
- Genetic alterations that make cancers susceptible to targeted therapies
Using Fluorescence In Situ Hybridization (FISH) technology, this test employs fluorescent DNA probes that bind to specific regions of the ROS1 gene. When rearrangements occur, the normal probe pattern changes, allowing for precise detection of genetic abnormalities that conventional methods might miss.
Who Should Consider This Test?
Clinical Indications and Symptoms
This test is particularly recommended for patients with:
- Advanced non-small cell lung cancer (NSCLC), especially adenocarcinoma
- Patients who are non-smokers or light smokers with lung cancer
- Individuals with metastatic lung cancer requiring treatment planning
- Patients who have exhausted standard chemotherapy options
- Those with family history suggesting genetic predisposition to lung cancer
Common symptoms that might indicate the need for testing include persistent cough, shortness of breath, chest pain, unexplained weight loss, and coughing up blood. However, the decision to test should always be made in consultation with an oncologist based on comprehensive clinical evaluation.
Benefits of Taking the FISH ROS1 6q22 Rearrangement Test
Undergoing this genetic analysis provides multiple significant advantages:
- Personalized Treatment Selection: Identifies patients who may benefit from ROS1 inhibitor therapies
- Improved Treatment Outcomes: Targeted therapies often show better response rates than conventional chemotherapy
- Reduced Side Effects: Targeted treatments typically have fewer side effects compared to traditional chemotherapy
- Informed Decision Making: Provides crucial information for developing comprehensive treatment plans
- Prognostic Information: Helps predict disease course and potential treatment responses
- Clinical Trial Eligibility: May qualify patients for specialized clinical trials and novel therapies
Understanding Your Test Results
Interpretation Guidance
Your FISH ROS1 6q22 Rearrangement Test results will typically fall into one of these categories:
Positive Result
A positive result indicates the presence of ROS1 gene rearrangement. This finding suggests that your cancer may respond well to specific targeted therapies called ROS1 inhibitors. Your oncologist will discuss appropriate treatment options, which may include medications specifically designed to target ROS1 fusion proteins.
Negative Result
A negative result means no ROS1 rearrangement was detected. While this excludes one specific targeted therapy option, your healthcare team will explore other treatment strategies and potentially recommend additional genetic testing for other targetable mutations.
Inconclusive Result
In some cases, results may be inconclusive due to technical factors or sample quality. Your healthcare provider may recommend repeat testing or alternative diagnostic approaches to obtain definitive information.
Important: Always discuss your results with your oncologist or genetic counselor, who can provide personalized interpretation based on your complete medical history and clinical context.
Test Pricing and Availability
| Test Component | Price (USD) |
|---|---|
| FISH ROS1 6q22 Rearrangement Test – Discount Price | $212 |
| FISH ROS1 6q22 Rearrangement Test – Regular Price | $300 |
Turnaround Time and Sample Requirements
- Turnaround Time: Samples accepted daily by 4 pm; Reports available in 4 working days
- Sample Type: Formalin fixed paraffin embedded tissue block
- Shipping: Ship at room temperature
- Tissue Requirements: Tissue block must contain minimum 10% tumor tissue
- Documentation: Duly filled Chromosome & FISH analysis Requisition Form (Form 17) is mandatory
Nationwide Availability and Booking
GGC DNA has comprehensive testing facilities across the United States, with branches in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many other cities. Our nationwide network ensures accessible, high-quality genetic testing services for patients throughout the country.
Take the next step in your cancer care journey with confidence. Our experienced genetic counselors and oncology specialists are ready to assist you with comprehensive testing and personalized guidance.
Book Your Test Today
Ready to schedule your FISH ROS1 6q22 Rearrangement Test? Contact our dedicated patient services team to book your appointment or discuss any questions you may have about the testing process.
Call or WhatsApp: +1(267) 388-9828
Our team is available to assist with scheduling, insurance questions, and providing detailed information about the testing process. Don’t delay this important step in your cancer treatment planning – reach out today to schedule your comprehensive genetic analysis.
